Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.

Trial Profile

Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 22 May 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-000342-32).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top